top of page
Search

EMA Grants LIfT 'ATMP Classification'

  • Writer: Alex Blyth, CEO
    Alex Blyth, CEO
  • May 2, 2017
  • 1 min read

Updated: Oct 11, 2022

The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP).

LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a medical procedure) in an orphan disease like Pancreatic Cancer, gives LIfT BioSciences significant advantages in getting to market faster with the Early Access Scheme off a single step trial and a Market Exclusivity license. Subject of course to the planned small clinical trial showing the same kind of great results we have seen in the lab. But this is certainly an important step forward".

 
 
 

Comentarios


Ya no es posible comentar esta entrada. Contacta al propietario del sitio para obtener más información.

LATEST NEWS

Stay up-to-date with our progress and latest news
Company

UK Office
LIfT BioSciences
London BioScience Innovation Centre

2 Royal College Street,
London,
England,

NW1 0NH
United Kingdom,

Company Reg: 09277638

Ireland Office
Eolaíocht Bhitheach LIfT Teoranta

Páirc Na Meán, Spiddal West 

An Spidéal

Co. Galway

H91 CH01

Ireland

US Office
Lift Biosciences Inc

265 Franklin Street

Suite 1702

Boston 02110

MA

United States of America

  • LIfTBio on Facebook
  • X
  • CEO's Linked-in
Quick Links

 

Copyright © 2025 LIfT BioSciences Ltd. All Rights Reserved.

bottom of page